The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
 
Natalie I Vokes
Honoraria - Sanofi
Consulting or Advisory Role - Lilly; OncoCyte; Regeneron; Sanofi; Sanofi/Regeneron
Research Funding - Mirati Therapeutics; OncoCyte
Travel, Accommodations, Expenses - Regeneron
 
David R. Gandara
Honoraria - Amgen; Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Daiichi Sankyo Alliance; Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); Lilly; Novartis; Ocean Genomics (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst); Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Ahmet Sezer
Honoraria - Amgen (Inst); pfizer (Inst); Roche (Inst)
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Pfizer; Roche
Research Funding - Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; REGENERON; Roche
 
Saadettin Kilickap
No Relationships to Disclose
 
Mahmut Gumus
Honoraria - GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)
Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Igor Bondarenko
No Relationships to Disclose
 
Mustafa Özgüroğlu
Honoraria - Astellas Pharma; Janssen; Novartis; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Janssen
 
Miranda Gogishvili
No Relationships to Disclose
 
Haci M. Turk
No Relationships to Disclose
 
Irfan Cicin
Consulting or Advisory Role - Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly O. (Inst); Merck Sharp & Dohme (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Teva (Inst)
Speakers' Bureau - Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Dmitry Bentsion
No Relationships to Disclose
 
Jinrui Liu
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Nicholas Giangreco
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Fang Wang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Jean-Francois Pouliot
Employment - AstraZeneca; Regeneron
Stock and Other Ownership Interests - Merck; Regeneron
 
Giuseppe Gullo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Petra Rietschel
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Vladimir Jankovic
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron